Fig. 4: BBB traversing ability and relevant mechanisms of Ptzyme integrated chiral ZIFs. | Nature Communications

Fig. 4: BBB traversing ability and relevant mechanisms of Ptzyme integrated chiral ZIFs.

From: Chiral metal-organic frameworks incorporating nanozymes as neuroinflammation inhibitors for managing Parkinson’s disease

Fig. 4

A Schematic demonstration of the BBB pattern using transwell assay, (B) the fluorescence microscope images, and (C) the corresponding quantitative results of FITC-labeled Ptzyme integrated chiral ZIFs in the lower chamber of SH-SY5Y cells. The scale bars are 50 μm, n = 3 independent experiments. Data represent the mean ± SD. A representative image of three biologically independent samples from each group is shown. D Intracellular tracking of FITC-Ptzyme@D-ZIFs in bEnd.3 cells after staining cells with Lyso Tracker and Hoechst. The white arrows indicate the intracellular position of Ptzyme@D-ZIFs. The scale bars are 10 μm. A representative image of three biologically independent samples from each group is shown. E Lysosomal occupation detected by the ratio of fluorescence overlapped by lysosomes and Ptzyme@D-ZIFs, as well as the fluorescence intensity of bEnd.3 cells after treatment with  FITC-Ptzyme@D-ZIFs, n = 3 independent experiments. Data represent the mean ± SD. Internalization of (F, G) Ptzyme@D-ZIFs and (H, I) Ptzyme@L-ZIFs by bEnd.3 cells under treatment of various endocytosis inhibitors, n = 3 independent experiments. Data represent the mean ± SD. In control group, bEnd.3 cells were incubated with nanocomposites but without endocytosis inhibitors. Schematic illustrating the cellular endocytosis and transcytosis process of (J) Ptzyme@D-ZIFs and (K) Ptzyme@L-ZIFs. The statistical analyses were conducted using GraphPad Prism 8.0.2. The outcomes were compared via one-way ANOVA (with Tukey’s post hoc correction for multiple comparisons). “ns” indicates not significant.

Back to article page